Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study DOI Creative Commons
Cesare Ernesto Maria Gruber, Fabio Giovanni Tucci, Emanuela Giombini

и другие.

Journal of Medical Virology, Год журнала: 2024, Номер 96(5)

Опубликована: Май 1, 2024

Abstract Molnupiravir, an oral direct‐acting antiviral effective in vitro against SARS‐CoV‐2, has been largely employed during the COVID‐19 pandemic, since December 2021. After marketing and widespread usage, a progressive increase SARS‐CoV‐2 lineages characterized by higher transition/transversion ratio, characteristic signature of molnupiravir action, appeared Global Initiative on Sharing All Influenza Data (GISAID) International Nucleotide Sequence Database Collaboration (INSDC) databases. Here, we assessed drug effects whole‐genome sequencing 38 molnupiravir‐treated persistently positive outpatients tested before after treatment. Seventeen tixagevimab/cilgavimab‐treated served as controls. Mutational analyses confirmed that exhibits increased ratio seven days initiation molnupiravir. Moreover observed G‐>A compared to controls, which was not related apolipoprotein B mRNAediting enzyme, catalytic polypeptide‐like (APOBEC) activity. In addition, demonstrated for first time diversity complexity viral quasispecies.

Язык: Английский

COVID-19 therapeutics DOI
Daniele Focosi, Massimo Franchini, Fabrizio Maggi

и другие.

Clinical Microbiology Reviews, Год журнала: 2024, Номер 37(2)

Опубликована: Май 21, 2024

SUMMARYSince the emergence of COVID-19 in 2020, an unprecedented range therapeutic options has been studied and deployed. Healthcare providers have multiple treatment approaches to choose from, but efficacy those often remains controversial or compromised by viral evolution. Uncertainties still persist regarding best therapies for high-risk patients, drug pipeline is suffering fatigue shortage funding. In this article, we review antiviral activity, mechanism action, pharmacokinetics, safety therapies. Additionally, summarize evidence from randomized controlled trials on various antivirals discuss unmet needs which should be addressed.

Язык: Английский

Процитировано

12
Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study DOI Creative Commons
Cesare Ernesto Maria Gruber, Fabio Giovanni Tucci, Emanuela Giombini

и другие.

Journal of Medical Virology, Год журнала: 2024, Номер 96(5)

Опубликована: Май 1, 2024

Abstract Molnupiravir, an oral direct‐acting antiviral effective in vitro against SARS‐CoV‐2, has been largely employed during the COVID‐19 pandemic, since December 2021. After marketing and widespread usage, a progressive increase SARS‐CoV‐2 lineages characterized by higher transition/transversion ratio, characteristic signature of molnupiravir action, appeared Global Initiative on Sharing All Influenza Data (GISAID) International Nucleotide Sequence Database Collaboration (INSDC) databases. Here, we assessed drug effects whole‐genome sequencing 38 molnupiravir‐treated persistently positive outpatients tested before after treatment. Seventeen tixagevimab/cilgavimab‐treated served as controls. Mutational analyses confirmed that exhibits increased ratio seven days initiation molnupiravir. Moreover observed G‐>A compared to controls, which was not related apolipoprotein B mRNAediting enzyme, catalytic polypeptide‐like (APOBEC) activity. In addition, demonstrated for first time diversity complexity viral quasispecies.

Язык: Английский

Процитировано

2